Combined Therapy For Squamous Carcinoma Cells: Application of Porphyrin-Alkaloid Modified Gold Nanoparticles by Jarmila Králová et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
6 
Combined Therapy For Squamous Carcinoma 
Cells: Application of Porphyrin-Alkaloid 
Modified Gold Nanoparticles 
Jarmila Králová1, Kamil Záruba2, Pavel ġezanka1, Pavla Poučková3, 
Lenka Veverková1 and Vladimír Král1,4 
1Academy of Sciences of the Czech Republic, 
2Institute of Chemical Technology Prague,  
3Charles University in Prague,  
4Zentiva Development (Part of Sanofi-Aventis Group) 
Czech Republic 
1. Introduction 
Photodynamic therapy (PDT) is an established and useful modality for the clinical non-
invasive treatment of cancer. This therapy requires a photosensitizing agent 
(photosensitizer) selectively taken up by tumor cells, visible light, and molecular oxygen to 
generate highly reactive oxygen species (ROS), which ultimately cause tumor destruction. 
The specificity achieved from drug uptake selectivity combined with light targeting makes 
PDT an appealing approach.  
PDT consists of three phases: excitation of photosensitizers (PS) by light, production of ROS, 
and induction of cell death (Triesscheijn et al., 2006). In the first phase, irradiated light of a 
suitable wavelength, typically visible or near-infrared, excites the PS molecules. The light is 
generally selected to correspond with the maximum absorption wavelength of the PS. The 
PS molecules then absorb light energy and change to an excited singlet state. These excited 
molecules can fall back to their native state with emission of fluorescence. Thus, all PS 
molecules are also examples of fluorescent molecules. On the other hand, the molecules also 
have the ability to undergo an electron spin conversion to their triplet state followed by the 
transfer of this energy to oxygen molecules or to other substrate molecules in the 
surroundings which then react with oxygen. 
1.1 History of PDT 
The fact that sunlight can be used to treat a variety of diseases such as rickets, psoriasis, and 
skin cancer is known from ancient civilizations, i.e. Egyptian, Chinese and Indian (Ackroyd 
et al., 2001; Daniell & Hill, 1991; Fitzpatrick & Pathak, 1959). At the beginning of the 20th 
century the term “photodynamic action” was used by Tappeiner et al. to explain the 
oxygen-consuming chemical reactions induced by photosensitization (Moan & Peng, 2003; 
Szeimies et al., 2001). Tappeiner, in cooperation with Jesionek, successfully treated patients 
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suffering from stage II syphilis, lupus vulgaris, and superficial skin cancer with topical eosin 
red solution (Szeimies et al., 2001). In 1942, Auler and Banzer observed specific uptake and 
retention of hematoporphyrin in tumors followed by higher fluorescence in cancer cells as 
compared with the surrounding tissue, and induction of necrosis after irradiation (Szeimies 
et al., 2001). Afterwards, PDT had not been used until Dougherty initiated revitalization by 
treating a group of patients suffering from cutaneous and subcutaneous tumors with the 
injection of photosensitizer dihematoporphyrin and red light produced by laser. The 
majority of the treated tumors showed either complete or partial remission (Dougherty et 
al., 1975; Dougherty et al., 1978; Szeimies et al., 2001).  
Particularly, PDT has grown in reputation in dermatology, mostly due to the simple 
accessibility of light exposure for the skin and the simplicity of topical use of 
photosensitizers. In the late 1970s, Thomas Dougherty initiated human clinical trials of PDT 
with hematoporphyrin derivative (HpD) for the treatment of cutaneous cancer metastases 
(Blume & Oseroff, 2007; Dougherty, 1996; Zeitouni, 2003). PDT has been revived and has 
become more applicable to common dermatology since 1990, when Kennedy et al. 
introduced 5-aminolevulinic acid (ALA) (Fig. 1), a topical porphyrin precursor causing local 
accumulation of the endogenous photosensitizer protoporphyrin IX (PpIX) (Fig. 2) with no 
significant prolonged phototoxicity (Kennedy, 1990). Nowadays, PDT is used to treat 
diseases in a variety of fields, including respiratory medicine (Ost, 2001; Sutedja & Postmus, 
1996), urology (Jichlinski, 2006; Juarranz et al., 2008; Pinthus et al., 2006), ophthalmology 
(Mittra, 2002), and gastroenterology (Barr et al., 2001; Wiedmann & Caca, 2004), as well as 
dermatology. Mostly porphyrins or phthalocyanines have been studied (Marmur et al., 
2004). On the other hand, for dermatological purposes, only hematoporphyrin derivatives 
such as porfimer sodium, or PpIX-inducing precursors such as ALA or methyl 
aminolevulinate (MAL) are of useful concern. As systemic photosensitizing drugs caused 
extended phototoxicity (Marmur et al., 2004), topical photosensitizers are preferred for the 
use in dermatology. Several drugs containing ALA or MAL are used for treating epithelial 
cancers and there is an increasing importance in the use of PDT (Braathen, 2001; Dragieva et 
al., 2004a; Dragieva et al., 2004b). 
H2N OH
O
O  
 
Fig. 1. Structure of 5-aminolevulinic acid 
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Fig. 2. Structure of protoporphyrin IX 
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1.2 Mechanism of PDT 
PDT requires an interaction of three key elements: light, a photosensitizer, and oxygen. 
After exposure to particular wavelengths of light, the photosensitizer is excited from a 
ground state (S0) to an excited singlet state (S1) (Fig. 3) followed by intersystem crossing to a 
longer-living excited triplet state (T1).  
 
Fig. 3. Mechanism of PDT; State energies are represented by thick lines:  
         porphyrin sensitizer,          dioxygen; reactive dioxygen intermediates are in bold  
After that, the photosensitizer at T1 state is able to go through two types of reaction with 
nearby molecules: either a type I reaction through hydrogen or electron transfer generating 
free radicals, or a type II reaction through energy transfer to oxygen, creating molecular 
singlet oxygen (1O2). The type I reaction results in generation of reactive free radicals or 
radical ions, which then react with ground-state molecular oxygen to produce superoxide 
anion radicals, hydrogen peroxides and hydroxyl radicals (Foote, 1991). The type II reaction 
produces singlet oxygen which has an important role in the molecular processes initiated by 
PDT (Foote, 1991; Niedre et al., 2002).The singlet oxygen has a lifetime approx. 3 s and can 
diffuse no more than 0.07 m in cells (Moan, 1990; Hatz at al., 2007). Therefore, the initial 
damage is limited to the site of the PS molecule. This is usually the mitochondria, Golgi 
apparatus, plasma membrane, endosomes, lysosomes, and endoplasmic reticulum (Buytaert 
et al., 2007). Damage to the subcellular organelles and plasma membrane eventually leads to 
apoptotic, autophagic and/or necrotic cell death. Generally, PS molecules localized to the 
mitochondria or the endoplasmic reticulum cause apoptosis, while localization either in the 
plasma membrane or lysosomes is found to delay or block the apoptotic pathway. On the 
other hand, if the apoptotic route is blocked, damaged cells still die using the autophagic or 
necrotic pathways (Buytaert et al., 2007; Oleinick et al., 2002). Latest studies support 
apoptosis as probably the preferred path to cell death (Buytaert et al., 2007). Even though it 
is considered that 1O2 is the main cytotoxic species and starts the pathway responsible for 
the damaging effects of PDT, free radicals formed by type I reactions significantly contribute 
to cell death as well (Foote, 1991). 
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1.3 Photosensitizers in PDT 
The first generation of PS molecules was represented by HpD or its purified version 
porfimer sodium (Photofrin) (Fig. 4). Primarily, they were used as general PS and tested for 
cutaneous malignancies. On the other hand, general intravenous administration and the 
consequential prolonged phototoxicity, which can last 6–10 weeks, restricted their use 
(Dragieva et al., 2004; Fritsch et al., 1998).  
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Fig. 4. Structure of Photofrin 
Second generation PS molecules such as m-tetrahydroxyphenyl-chlorin, tin ethyl 
etiopurpurin, phthalocyanines, and chlorins (Fig. 5) are pure compounds that can be 
activated by light wavelengths in the range of 660–690 nm. Most significantly, they all have 
a lower tendency to cause prolonged photosensitivity compared with the first generation of 
photosensitizers (Moan & Berg, 1992). 
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Fig. 5. Structure of m-tetrahydroxyphenyl-chlorin (a), tin ethyl etiopurpurin (b), 
phthalocyanines (c), and chlorins (d) 
Third generation PS molecules (not yet approved) consist of antibody-conjugated PS 
(Josefsen & Boyle, 2008) and lutetium texaphyrin (Fig. 6) (Woodburn et al., 1998; Young et 
al., 1996). These drugs supporting deeper penetration into tissue with absorptions of 700–
800 nm accumulate in tumor tissues with high selectivity. 
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Fig. 6. Structure of lutetium texaphyrin 
To avoid the prolonged photosensitivity caused by systemic administration, topically 
applied photosensitizers have been developed for the treatment of skin cancers. The most 
successful commercially accessible topical drugs are ALA and its methyl ester MAL. 
Levulan® using ALA and the Blu-U light source was accepted by the U. S. Food and Drug 
Administration for the treatment of nonhyperkeratotic actinic keratoses of the face and scalp 
in 1999 (Babilas et al., 2005; Kormeili et al., 2004). MAL was accepted in Europe for topical 
PDT of actinic keratosis (AK) and basal cell carcinoma (BCC) in 2001 (Morton, 2003; Morton 
et al., 2002) and for the treatment of AK in the USA in 2004 (Zeitouni et al., 2003; Garcia-
Zuazaga et al., 2005). The endogenous photosensitizer PpIX generated from ALA or MAL 
can be fully metabolized to photodynamically inactive heme over 24–48 h (Blume & Oseroff, 
2007; Morton, 2004), which radically decreases the unpleasant side effect of prolonged 
cutaneous phototoxicity. 
1.4 Nanoparticles in PDT 
In 2002 Konan et al. divided methods of PS molecules delivery into passive and active based 
on the presence or absence of a targeting molecule on the surface (Konan et al., 2002). The 
methods employed to bring the PS explicitly into diseased tissues using the target tissue 
receptors or antigens were designated active, whilst others that enable parenteral 
administration and passive targeting, such as PS conjugates of oil-dispersions, polymeric 
particles, liposomes, and hydrophilic polymers, were named passive. Active nanoparticles 
can be subclassified by their mechanism of activation and passive nanoparticles can be 
subclassified by material composition into (a) non-polymer-based nanoparticles, e.g. 
ceramic and metallic nanoparticles, and (b) biodegradable polymer-based nanoparticles. 
1.4.1 Active nanoparticles 
 Photosensitizer nanoparticles 
Quantum dots (QDs) have great photostability, intensive fluorescent emission (high 
quantum yields) and possible use in specific pathological fields. They can be water soluble, 
and transfer energy to surrounding oxygen with resulting cellular toxicity. Many studies 
have been devoted to this field (Bakalova et al., 2004). The first report deals with cadmium 
selenide (CdSe) QDs and was published by Samia at al. in 2002. The authors presented the 
possibility to use semiconductor QDs alone to generate 1O2 due to the intercalation of 
dissolved oxygen at the QD surface (Samia et al., 2003). They predicted a comparable 
interaction in water-soluble phospholipid-capped QDs. Moreover, they assumed that since 
the lowest excited state of CdSe QDs is a triplet state, the energy transfer was responsible for 
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the generation of singlet oxygen (1O2) from triplet oxygen (3O2). On the other hand, the 
efficiency of generation of 1O2 was about 5% (with 65% emission quantum yield of QDs) as 
compared to 43% for the PS only. It may be due to carrier trapping and nonradiative carrier 
recombinations occurring on the early picosecond time scale and the very small fraction of 
QD - 3O2 pairs created at any moment (Samia et al., 2003). To avoid the ineffectiveness of 
QDs alone to produce singlet oxygen, several experiments have been carried out to 
covalently conjugate PSs to CdSe/ZnS via organic bridges (Hsieh et al., 2006; Samia et al., 
2003). These experiments have a frequent problem with lower water solubility. 
 Self-lighting nanoparticles 
Scintillation or persistent luminescence nanoparticles with attached PS molecules such as 
porphyrins were applied as in vivo agents for PDT (Auzel, 2004). After exposure to ionizing 
radiation such as X-rays, scintillation luminescence is produced from the nanoparticles and 
stimulates the photosensitizers, followed by production of singlet oxygen that increases the 
destruction of cancer cells by ionizing radiation. Employment of common radiation therapy 
with PDT allows application of lower doses of radiation. Using BaFBr:Eu+,Mn+ 
nanoparticles displaying luminescence, short X-ray exposures could be applied followed by 
extended PS excitation. The period of phosphorescent decay is increased in vivo due to 
higher local temperatures (Chen et al., 2006). 
 Upconversion nanoparticles 
Upconversion and simultaneous two-photon absorption occurs in luminescent materials 
with triplet excitation states (Auzel, 2004). Upconverting nanoparticles are modified 
nanometer-sized composites that generate higher energy light from lower energy radiation 
typically near or middle infrared (anti-Stokes emission) using transition metal ions doped 
into a solid-state host (Boyer et al., 2006; Pires et al., 2006). For biological use, the desired 
nanocrystalline core should have morphological and optical features that are appropriate for 
conjugation with biological molecules and exhibit high intensity emission as well (Pires et 
al., 2006). Preparation of high-quality nanocrystals is needed, and the surface properties and 
growth dynamics must be precisely controlled (Wang et al., 2006). Upconversion 
nanoparticles can be prepared via numerous different ionic materials – typically rare earth 
ions such as lanthanides and actinides doped in a suitable crystalline matrix (Zijlmans et al., 
1999). Micrometer-sized Er3+/Yb3+ or Tm3+/Yb3+ co-doped hexagonal NaYF4 are examples 
of nanoparticles that exhibit the highest upconversion efficiencies (Heer et al., 2004) and are 
precursors of upconverting nanoparticles with biological applications (Zhang et al., 2006). In 
2006, the NaYF4 nanocrystals doped with Er and Yb and coated with organic polymers were 
prepared and strong emission upon activation with 980 nm NIR laser was shown (Feng et 
al., 2006). One year later, Zhang et al. used upconverting nanoparticles (nanoparticles of 
NaYF4:Yb3+,Er3+ coated with a porous thin layer of silica doped with merocyanine and 
functionalized with a tumor-targeting antibody) in PDT, but these nanoparticles were not 
activated in depth in animal tissue and the efficiency in killing cancer cells was very low 
(Zhang et al., 2007). 
Another class of employed upconversion nanoparticles consists of zinc pthalocyanine 
(ZnPC) (Fig. 7) physically adsorbed to the surface of the nanoparticles with the 
encapsulation efficiency of 98 % (Ricci-Junior & Marchetti, 2006b). The fluorescence 
excitation spectrum of ZnPC exhibits an excitation maximum at 670 nm and greatly overlaps 
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the red emission peak for the upconversion nanoparticles. Creation of 1O2 by irradiation of 
the ZnPC-nanoparticle complex with 980 nm light was confirmed through the 
photobleaching of disodium 9,10-anthracenedipropionic acid (Wieder et al., 2006). 
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Fig. 7. Structure of zinc pthalocyanine 
1.4.2 Passive nanoparticles 
 Non-biodegradable nanoparticle carriers 
In 2003 Roy et al. first reported ceramic-based nanoparticles used as a new drug-carrier 
system for PDT. It utilizes 30-nm silica-based spherical particles doped with the anticancer 
drug 2-devinyl-2-(1-hexyloxyethyl)pyropheophorbide (Fig. 8) (Roy et al., 2003).  
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Fig. 8. Structure of 2-devinyl-2-(1-hexyloxyethyl)pyropheophorbide 
Irradiation of the nanoparticles with light of appropriate wavelength led to efficient creation of 
singlet oxygen. On the other hand, noncovalent adsorption of PS into porous silica 
nanoparticles led to drug leakage. Covalent bonding of the PS into organically modified silica 
nanoparticles produced more stable material (Ohulchanskyy et al., 2007). Organically 
modified silica nanoparticles were also used for two-photon dye encapsulation (Kim et al., 
2007). Cinteza et al. described a combination of magnetism and PDT using micellar polymeric 
diacylphospholipid-poly(ethylene glycol) capsules for encapsulation of the 2-devinyl-2-(1-
hexyloxyethyl)pyropheophorbide PS and magnetic Fe3O4 nanoparticles (Cinteza et al., 2006). 
In contrast to the previous report (Kim et al., 2007), the magnetic nanoparticles were used for 
targeted delivery of PS to tumor cells and increased imaging (Cinteza et al., 2006). Wieder at el. 
described a delivery system consisting of gold nanoparticles modified with phthalocyanine 
(Wieder et al., 2006). Phthalocyanine derivative-modified gold nanaoparticles have 2-4 nm in 
diameter and have a maximum absorption peak at 695 nm. They generated 1O2 catalytically 
with high efficiency. Upon irradiation of these nanoparticles, significant improvement in PDT 
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efficiency was observed, probably thanks to 50% increase of 1O2 quantum yields as compared 
to the free PS. In the same year El-Sayed reported efficient conversion of strongly absorbed 
light by plasmonic gold nanoparticles to heat energy. Easy bioconjugation of nanoparticles 
used suggests their application as selective photothermal agents in molecular cancer cell 
targeting (El-Sayed et al., 2006). 
Two-photon dyes have received attention lately because of their ability to convert absorbed 
low-energy radiation to higher energy emissions. Dyes that can direct transfer of the higher 
energy to molecular oxygen for generation of 1O2 can be very useful in PDT because they 
can be activated in deep tissues. The first use of two-photon dyes that are able to convert 
absorbed low-energy radiation to higher-energy emissions was recently reported using 
microemulsion to incorporate the two-photon dye porphyrin tetra(p-toluenesulfonate) into 
polyacrylamide nanoparticles (Gao et al., 2006). 
 Biodegradable nanoparticle carriers 
Biodegradable polymeric nanoparticles allow high drug loading and controlled drug 
release. They exist in a large variety of materials (Konan et al., 2002). Modifying the surface 
of nanoparticles with polymers such as poly(ethylene glycol) and poly(ethylene oxide) 
increases circulation times (McCarthy et al., 2005). Brasseur et al. described 
hematoporphyrin adsorbed in polyalkylcyanoacrylate nanoparticles (Brasseur et al., 1991), 
but the resulting materials showed poor carrier capacity and rapid drug release. 
Encapsulation of tetrasulfonated zinc phthalocyanine or aluminium naphthalocyanine into 
poly(isobutylcyanoacrylate) or poly(ethylbutylcyanoacrylate) nanocapsules or nanosphere 
was published in the same year (Labib et al., 1991). Then, second generation phthalocyanine 
derivatives were used in PEG-poly(lactic acid) nanoparticles (Allemann et al., 1995). The 
results showed that immobilization in the biodegradable nanoparticle improved PDT 
response of the tumor in contrast to conventional Cremophor EL emulsion by providing 
prolonged tumor sensitivity towards PDT (Allemann et al., 1995). After a few years, Konan 
et al. developed polyester poly(D,L-lactide-coglycolide) and poly(D,L-lactide) doped with 
PS with much higher loading than ever published before (Konan et al., 2003a; Konan et al., 
2003b). In order to further investigate these nanoparticles, the efficacy of the encapsulated 
drug was assessed on the chick embryo chorioallantoic membrane model (Vargas et al., 
2004). In another work the in vitro and in vivo photodynamic activities of verteporfin-loaded 
poly(D,L-lactide-coglycolide) nanoparticles were studied. The results showed improved 
photodynamic activity of PS (Konan-Kouakou et al., 2005). 
The problem with side photosensitivity due to non-specific localization of the PS into 
healthy tissue or skin was studied by McCarthy et al., who developed a new nano-agent that 
has several desirable properties for use as photodynamic drug including no toxicity in 
extracellular spaces and time-dependent intracellular release of PS (McCarthy et al., 2005). 
They demonstrated in cell culture that the phototoxicity caused by non-internalized 
nanoparticles is minimal (9% cell death) in contrast to the effect of internalized nanoparticles 
(95% cell death under identical testing conditions) (Dougherty et al., 1978). In another study 
Ricci-Junior et al. reported the preparation, characterization, and results of the phototoxicity 
assay of poly(D,L-lactide-coglycolide) nanoparticles containing ZnPC for PDT use (Ricci-
Junior & Marchetti, 2006a). Other photosensitizers that have been studied consist of 
Indocyanine green (Saxena et al., 2006) and Hypericin (Zeisser-Labouebe et al., 2006). These 
compounds have the potential to be used for both diagnostic and therapeutic purposes. 
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1.5 Combined therapy 
Even if PDT has been used effectively for treating various tumors, it still has several 
restrictive factors for a target-specific response, such as an observed angiogenic effect and 
pronounced inflammatory reaction after PDT treatment (Pervaiz & Olivo, 2006). PDT in 
combination with other types of therapy is an attractive approach to suppress these 
problematic side effects.  
PDT-induced hypoxia has been associated with an increase in the expression of many 
angiogenic growth factors, such as hypoxia-inducible factor 1 (HIF-1), fibroblast growth 
factor receptor-1(FGFR-1), cyclooxigenase-2 (COX-2), and vascular endothelial growth factor 
(VEGF). Combination therapy using antiangiogenic agents (e.g., COX-2 or VEGF inhibitors) 
with PDT led to a significant decrease of PDT-induced expression of prostaglandin E2 and 
VEGF, as well as a marked improvement in tumoricidal response (Akita et al., 2004; Ferrario 
et al., 2002; Zhou et al., 2005). 
In contrast to radiotherapy, surgery or chemotherapy, PDT can lead to a strong acute 
inflammatory response, generally as tumor-localized edema. This PDT-induced immune 
activation makes it possible to positively reverse the tumor–host relationship from one that 
is tumor dominated to one that is oriented against the tumor. The combination with 
immunotherapy can reinforce the immune response triggered by PDT and thus significantly 
improve the anti-tumor immune response (Pervaiz & Olivo, 2006). Numerous recent clinical 
trials conclude that enhanced clinical outcomes can be achieved by a combination of ALA-
PDT and immunomodulation therapy for the treatment of premalignant skin diseases, such 
as Bowen’s disease (BD), BCC and AK (Wang et al., 2007; Wang et al., 2008). 
In several cases, combination therapy can be done by linking the photosensitizer directly to 
an anticancer drug or to a specific antibody to target highly tumor-expressed receptors 
(Palumbo, 2007). It would also be easily accomplished by combining them using 
nanotechnology. 
1.6 Light sources in PDT 
A variety of light sources that are used in PDT consist of light-emitting diodes (LEDs), 
filtered xenon arc and metal halide lamps, fluorescent lamps, and lasers. Lasers and filtered 
broadband sources provide comparable efficacy in topical PDT (Clark et al., 2003). Non-laser 
light sources are also important in topical PDT, because in contrast to lasers they are stable, 
cheap, and offer broad-area illumination fields. Recently, LEDs showed significant progress 
in design, creating these low-cost sources suitable for broad-area irradiation, and were 
accepted for patient use. These LEDs are focused on the 630-to-635-nm activation peak of 
PpIX while excluding the inappropriate wavelengths present in broadband sources, thus 
allowing shorter irradiation times. Biophysical calculations show that LEDs with peak 
emission of 631 ± 2 nm can have a deeper PDT action in tissue than filtered halogen lamps 
with 560–740 nm emission, and hence LEDs may be more successful in treating the deeper 
parts of tumors (Juzeniene et al., 2004). 
PpIX has its main absorption peak in the blue region at 410 nm (Soret band) with smaller 
absorption peaks at 505, 540, 580 and 630 nm. Most light sources for PDT seek to utilize the 
630-nm absorption peak, in order to improve tissue penetration. On the other hand, a blue 
fluorescent lamp (peak emission 417 nm) is usually used. Nowadays, there are several reports 
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that blue, green, and red light itself can be efficient in topical PDT of AK; however, the more 
deeply penetrating red light is better when treating BD and BCC (Morton et al., 2002). 
The concept of ambulatory PDT to decrease hospital attendance for PDT was described by 
Moseley et al. (Moseley et al., 2006). In a study of five patients with BD, PDT was carried out 
with ALA and a portable LEDs device. Current studies have suggested that pulsed light 
therapy may be helpful for treatment in topical PDT of acne, AK and photorejuvenation. On 
the other hand, a recent controlled investigative study carried out in healthy human skin in 
vivo demonstrated that two pulsed light sources formerly reported in PDT brought evidence 
of minimal activation of photosensitizer, with a significantly smaller photodynamic reaction 
than observed with a conventional continuous wave broadband source (Strasswimmer & 
Grande, 2006). These sources deliver intense light in short periods (< 20 ms), which might 
suppress oxygen consumption (Kawauchi et al., 2004). Unplanned ambient light exposure 
may have considerably contributed to the clinical effect. However, three studies have 
recently addressed the possibility of using ambient light for ALA-PDT of AK (Batchelor et 
al., 2007; Marcus et al., 2007; Strasswimmer & Grande, 2006). Two of them report on 
therapeutic advantage. Nevertheless, the randomized ambient light-controlled study using 
ALA demonstrated no significant effect on lesion ablation. A randomized right⁄left intra-
patient evaluation of conventional MAL-PDT combined with LEDs device versus daylight 
(for 2.5 h) for the treatment of AK of face and scalp demonstrated corresponding reduction 
in AK and significantly less pain with daylight (Wiegell et al., 2008). 
Total effective light dosage is proposed as a concept for optimizing the accuracy of light 
dosimetry in PDT considering incident spectral irradiance and optical transmission through 
tissue and absorption by PS (Moseley, 1996). Actually, light dosimetry is explained as the 
irradiance rate (mW cm–2) at the skin surface and the total dosage (J cm–2) distributed to the 
surface, the second being a product of irradiance and time of exposure.  
It has been suggested that lower fluence rates and fractionation of light exposure can 
improve lesional reaction by promotion of the photodynamic reaction (Henderson et al., 
2004). A study of superficial BCC illuminated with 45 J cm–2 at 4 h and repeated at 6 h with 
633-nm laser light at 50 mW cm–2 showed a total response of 84 % after a mean of 59 months 
(Star at el., 2006). Newer studies support advantages of the fractionation approach in BCC, 
although not in BD (Haas et al., 2006; Haas et al., 2007). 
1.7 Synthetic meso-tetraphenylporphyrins in PDT 
Extensive information about the application of various porphyrins and their derivatives in 
PDT has been published (Král et al., 2006). Accordingly, our laboratory synthesized 
porphyrin conjugates with glycol (Králová et al., 2008a), bile acid (Králová et al., 2008b), and 
cyclodextrins (Králová et al., 2006) and their in vitro and in vivo PDT activity has been tested. 
It was shown that these porphyrin conjugates are taken up preferentially by tumor cells and 
have the potential to be used for PDT to selectively ablate tumors (Králová et al., 2006; 
Králová et al., 2008a; Králová et al., 2008b). 
Our contemporary strategy is to combine favorable features of gold nanoparticles mediating 
the photothermal effect with a photosensitizing compound mediating the photodynamic effect 
into one combined modality and thus introduce a therapeutic protocol efficient against SCC. 
The key steps in our strategy are: i) generation of a synthetic ligand with photosensitizing 
properties, ii) ligand immobilization on the surface of modified gold nanoparticles to enable 
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combination of PDT and thermo-effect, and iii) verification of the biological activity by in 
vitro and in vivo studies. 
2. Experimental 
2.1 Preparation of modified gold nanoparticles 
Porphyrin–brucine conjugates 1 and 2 (Fig. 9) were prepared according to the procedure 
described previously (Král et al., 2005). Gold nanoparticles (14.7 nm) were prepared by citrate 
reduction of potassium tetrachloroaurate(III) (Au-citr). After modification with  
3- mercaptopropanoic acid, derivatives 1 and 2 were immobilized as described elsewhere 
(ġezanka et al., 2008). Here, a solution of 1 or 2 (5 mg) in methanol was added to 50 ml of Au-
citr. Modified nanoparticles (Au-1 and Au-2, respectively) were isolated by centrifugation after 
three days of incubation. Using redispersion in methanol, methanol–water, water and 
dimethylsulfoxide, unbound porphyrin derivatives were removed and Au-1 and Au-2 
molecules were concentrated to a volume of 1 ml. According to the spectral analysis of 
supernatants, 0.8 mg of 1 or 2 was present in the final 1 ml solution of Au-1 and Au-2 
nanoparticles. The core of modified nanoparticles was characterized by transmission electron 
microscopy and photon cross-correlation spectroscopy (Nanophox). The chemical 
modification, ligand, was analyzed by absorption and fluorescence spectrometry. Fluorescence 
spectra were recorded using a Fluoromax spectrometer (Jobin-Yvon, Japan). A volume of 1 ml 
of sample was placed into 1 cm plastic cuvettes. The excitation wavelength was 520 nm.  
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Fig. 9. The structure of 1 and 2 
2.2 Cell culture and in vitro experiments 
4T1 (mouse mammary carcinoma) and A431 (epidermal squamous carcinoma) cells were 
purchased from ATCC and PE/CA-PJ34 (human basaloid squamous cell carcinoma) cells 
were purchased from ETCC. As described before (Králová et al., 2006), all cells were grown 
exponentially in RPMI 1640 medium with 10% fetal calf serum. For photodynamic 
experiments, 1–1.5 x 105 cells were seeded into 1.8 cm-2 wells and incubated overnight with 
the porphyrin–brucine conjugates or their counterparts immobilized on gold nanoparticles 
(1 and 2.5 M). After incubation, cells were rinsed with PBS, cultured for 1 h in fresh 
medium without phenol red and illuminated with a 75 W halogen lamp with a band-pass 
filter (Andover, Salem, NH) that emitted light at wavelengths between 500–520 nm. The 
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fluence rate at the level of the cell monolayer was 1 mW cm-2, and the total light dose was 
7.2 J cm-2. Twenty-four hours post irradiation, the viability of PDT-treated cultures was 
determined by the Trypan blue exclusion method. In parallel, control “dark” experiments 
(without illumination) were performed.  
2.3 Microscopic studies 
Cells grown on coverslips in 35 mm Petri dishes were incubated with 2.5 M porphyrin–
brucine conjugates in culture medium for 16 h. After washing, porphyrin fluorescence was 
observed with a DM IRB Leica microscope equipped with a DFC 480 camera using a x63 oil 
immersion objective and Leica filter cube N2.1 (excitation filter BP 515–560 nm and long 
pass filter LP 590 nm for emission). To label lysosomes, 500 nM LysoTracker Green 
(Molecular Probes) was added to the culture media for 30 min. Cells were washed and 
examined by fluorescence microscopy using the Leica filter cube I3 (excitation filter BP 450–
490 nm and long pass filter LP 515 nm for emission).  
2.4 In vivo experiments 
For in vivo experiments, the immuno-compromised nude mice with subcutaneously implanted 
human SCC tumors were used. When the tumor mass reached a volume of 100 mm3 (10–14 
days after injection), mice were intravenously injected with porphyrin-brucine conjugates (5 
mg kg-1) resuspended in a volume of 0.1 ml per 20 g mice and six hours later the tumor area (2 
cm2) was irradiated with a 500–700 nm xenon lamp ONL051 (maximum at 635 nm, Preciosa 
Crytur, Turnov, Czech Republic) with a total impact energy of 100 J cm-2 and fluence rate of 
200 mW cm-2. Each experimental group consisted of five or eight mice. The tumor size was 
measured repeatedly and the tumor volume was determined (Králová et al., 2006). All aspects 
of animal experimentation and husbandry were carried out in compliance with national and 
European regulations and were approved by the institutional committee. 
3. Results and discussion 
3.1 Modification by gold nanoparticles 
Gold nanoparticles (14.7 nm) prepared by citrate reduction of potassium 
tetrachloroaurate(III) (Au-citr) were modified with 3-mercaptopropanoic acid, and the 
derivatives 1 and 2 were immobilized. Gold nanoparticles modified with 1 and 2 are 
designated Au-1 and Au-2, respectively. 
3.2 Fluorescence spectra 
The fluorescence intensity of 1 and 2 was strongly dependent on the solvent used. The 
influence of additional compounds on the intensity of emitted fluorescence wavelengths was 
tested by measuring the emission spectra (excitation of the first Q-band of porphyrins at 520 
nm) of 1 and 2 in water, an inorganic salt solution (corresponding to the cell culture media) 
supplemented with a 50 mg ml-1 solution of human serum albumin (HSA) (Fig. 10A). In 
comparison with water, the emission bands of 1 and 2 measured in the media were red-shifted 
(for 1, from 638 and 700 nm to 644 and 709 nm, and for 2, from 643 and 707 nm to 647 and 710 
nm) and the fluorescence intensity of 1 increased slightly whilst that of 2 decreased. After 
immobilizing the porphyrin conjugates on nanoparticles, the intensity of fluorescence emission 
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spectra significantly decreased (Fig. 10B) despite the concentration of porphyrins remained the 
same. The weak quantum yield may be attributed to that: (1) both porphyrins and 
nanoparticles absorb light at approximately 520 nm, (2) fluorescence quenching by porphyrin-
to-metal energy transfer, (3) partial aggregation of the modified nanoparticles. In the case of 
Au-1, aggregation seems to be the cause (Fig. 10B, compare traces “Au-1/water” and “Au-
1/medium”), as the intensity of emitted fluorescence was several times higher in cell culture 
medium compared to water only. These results demonstrate that both para- (1) and meta- (2) 
derivatives aggregate in a solution-dependent manner that is not affected by the presence of 
PS or immobilization on gold nanoparticles. Importantly, the presence of model plasma 
proteins present in the cell medium dramatically reduced the aggregation of modified 
nanoparticles. This observation led us to further test these compounds for in vivo PDT efficacy.  
 
 
Fig. 10. The fluorescence emission spectra of porphyrins 1 and 2 (left) and porphyrin-
modified nanoparticles Au-1 and Au-2 (right) in water and cell culture media. Excitation 
was performed at 520 nm. Porphyrin–brucine conjugates were used at a concentration of 3.5 
M. The concentration of human serum albumin used in growth medium was 50 mg ml–1. 
3.3 Intracellular localization 
The porphyrin–brucine conjugates (1 and 2) were next analyzed for tumor cell uptake and 
intracellular distribution. The mammary carcinoma cell line, 4T1 was cultivated in the 
presence of the conjugates for 16 h, during which time the cells were well-dispersed and 
growing mostly as planar sheets, enabling focused images of fluorescence to be recorded. 
These cells exhibited punctate red fluorescence (Fig. 11). 
A
B
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Fig. 11. The intracellular localization of porphyrin–brucine conjugates in 4T1 cells. The 
middle panels show the red fluorescence of 1 and 2 and co-staining with the lysosomal 
specific probe (LysoTracker Green); right panels represent an overlay of the green and red 
images and demonstrate co-localization (shown in orange/yellow). Porphyrin–brucine 
conjugates were used at a concentration of 2.5 M. 
To identify the intracellular compartment where 1 and 2 accumulate, co-staining with the 
LysoTracker Green fluorescence probe was performed. The merged images revealed that 1 
and 2 colocalized to a subset of LysoTracker-stained structures that represent lysosomes. 
Similar localization was also observed in PE/CA-PJ34 basaloid squamous cell carcinoma 
cells and A431 epidermal squamous carcinoma, cell lines that were predominantly used in 
our study (data not shown). Upon addition of gold nanoparticle-conjugated 1 and 2 to cell 
culture media, aggregates formed, which were visible as a reddish precipitate that covered 
parts of the cell. These were particularly abundant in the case of Au-1 (Fig. 12).  
 
Fig. 12. Difference in aggregation behavior of porphyrin–brucine conjugates immobilized on 
gold nanoparticles (left panels). 4T1 cells were incubated with Au-1 and Au-2 at a 
concentration of 2.5 M for 4 h before pictures were taken. Aggregates are highlighted by 
arrows. 
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3.4 In vitro phototoxicity 
To investigate the photodynamic potential of the free porphyrin–brucine conjugates or those 
immobilized on gold nanoparticles, we incubated PE/CA-PJ34 cells in the presence of the 
conjugates for 16 h and subjected them to PDT. In parallel, cells were incubated with 
porphyrins without illumination to serve as dark controls. Twenty-four hours following the 
illumination of cells with filtered light, the mortality of post-PDT cultures was determined 
(Fig. 13). 
 
Fig. 13. The effect of free or immobilized porphyrin–brucine conjugates on the induction of 
cell death via PDT. PE/CA-PJ34 cells were incubated with either 1 or 2.5 M of 1 and 2 or 
their modified Au-nanoparticles for 16 h. Cells were then illuminated with filtered light 
(500–520 nm, 7.2 J cm–2). The percentage of dead cells was established the following day by 
using the Trypan blue exclusion method. The average and standard deviation for three 
independent experiments is shown. 
Satisfyingly, the induction of cell death was both light and drug-dose dependent. Control 
cells incubated with unconjugated gold nanoparticles (Au-citr) did not display any increase 
in cell death after illumination. Thus, under these in vitro conditions we can exclude the 
possibility that any case of cell death is due to the photothermal activity of the gold 
nanoparticles. Interestingly, the phototoxicities of unbound porphyrin–brucine conjugates 1 
and 2 were higher than those immobilized on gold nanoparticles. This reduction of 
photodynamic efficacy is likely to be a consequence of Au-1 and Au-2 aggregation that 
occurs in the aqueous cell growth media (Fig. 12).  
3.5 In vivo PDT efficacy 
Using an in vivo mouse cancer model, the PDT effectiveness of the unbound porphyrin–
brucine conjugates 1 and 2 was compared with those immobilized on gold nanoparticles 
(Au-1, Au-2). Nude mice (NuNu) bearing basaloid squamous cell carcinoma PE/ CA-PJ34 
cells received by intravenous injection either unmodified porphyrins or their gold 
nanoparticle-modified counterparts. Six hours post injection, tumors were illuminated 
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with light at a dose of 100 J cm–2. Mice not injected with unmodified porphyrins or 
nanoparticles served as controls. Tumor size was measured after PDT at regular intervals 
(Fig. 14). 
 
Fig. 14. The PDT effectiveness of 1 and 2 and their respective Au-immobilized nanoparticle 
counterparts to eradicate mouse tumors. Nude mice (NuNu) bearing subcutaneous PE/CA-
PJ34 tumors (n = 8 per each group) received an intravenous dose of the drug (5 mg kg–1). 
Tumors were illuminated with light (100 J cm–2) six hours after injection. The tumor size was 
measured repeatedly and the tumor volume was determined. Control mice were exposed to 
illumination but did not receive the porphyrin drug. The Au-citr group represents mice 
injected with Au nanoparticles, 1 and 2 groups received porphyrin conjugates, Au-1 and 
Au-2 groups received porphyrin-modified Au nanoparticles. 
We observed the greatest reduction in tumor growth in mice treated with Au-1 and Au-2. 
All tumors were eliminated in animals that received these conjugated porphyrins and 
importantly, no detectable relapse of the primary tumor was observed. In contrast, animals 
treated with unbound 1 and 2 exhibited only a transient regression in tumor size that lasted 
until day 18, when the primary tumors began to gradually regrow. Presumably, this relapse 
in tumor growth comes from the small population of tumor cells that survived the PDT. 
Interestingly, mice treated with unconjugated gold nanoparticles exhibited slight tumor 
retardation in growth, which is most likely due to the photothermal effect described in other 
systems (Gamaleia et al., 2010; O’Neal et al., 2010; ġezanka et al., 2008).  
These results clearly show that porphyrin alkaloid-modified gold nanoparticles are very 
effective against basaloid SCC in vivo. To verify more general applicability of porphyrin 
alkaloid-modified gold nanoparticles, the same approach was used against epidermal SCC 
tumors (Fig. 15). A431 cells formed fast progressing subcutaneous tumors, which were 
completely eradicated after Au-2-mediated PDT treatment in 60% mice or their growth was 
substantially reduced. These results demonstrate a high potential of porphyrin alkaloid-
modified gold nanoparticles to fight SCC.  
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Fig. 15. The PDT effectiveness of Au-2 against fast progressing epidermal squamous 
carcinoma A431. Nude mice (NuNu) bearing subcutaneous A431 tumors (n = 5 per each 
group) received an intravenous dose of the drug (5 mg kg–1). Tumors were illuminated with 
light (100 J cm–2) six hours after injection. The tumor size was measured repeatedly and the 
tumor volume was determined. Control mice were exposed to illumination but did not 
receive the porphyrin drug. The Au-citr group represents mice injected with Au 
nanoparticles without porphyrin. 
The apparent discrepancy in the in vitro and in vivo performance of unbound porphyrin–
brucine conjugates 1 and 2 and those immobilized on gold nanoparticles (Au-1 and Au-2) is 
likely to be due to the differing environmental conditions to which the porphyrin conjugates 
were exposed. The fluorescence data revealed that conjugates 1 and 2 were efficiently taken 
up by cells under the in vitro conditions tested. However, in culture media, Au-1 and Au-2 
tended to aggregate, which resulted in their lower intracellular availability (Fig. 12) and 
lower PDT efficacy (Fig. 13). Under the in vivo conditions tested, the gold nanoparticle-
immobilized conjugates were more effective than free conjugates alone. Both spectroscopic 
and ECD studies demonstrated that conjugated nanoparticles exhibited a strong interaction 
with plasma proteins (mainly HSA), which led to their self-assembly and to generation of 
supramolecular complexes. Subsequently, thanks to the enhanced permeability and 
retention (EPR) effect resulting in potent accumulation of Au-1 and Au-2 in the tumors, their 
PDT efficacy was increased. Moreover, the direct lethal effect of PDT on tumor cells 
combines well with the nanoscale size of gold-immobilized porphyrins that may limit the 
local blood supply (vascular impairment). This hypothesis of vascular damage after PDT 
with nanoparticles will be the subject of future work. 
4. Conclusion 
The spectroscopic studies demonstrated that fluorescence intensity of free and immobilized 
conjugates were strongly dependent on the solvent used. After immobilizing the porphyrin 
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conjugates 1 and 2 on nanoparticles, the intensity of fluorescence emission spectra significantly 
decreased. The weak quantum yield may be attributed to that: (1) both porphyrins and 
nanoparticles absorb light at approximately 520 nm, (2) fluorescence quenching by porphyrin-
to-metal energy transfer, (3) partial aggregation of the modified nanoparticles. Importantly, the 
presence of model plasma proteins in the cell medium dramatically reduced the aggregation of 
modified nanoparticles and prompted their use in vivo. 
The evaluation of the biological activity of porphyrin-brucine conjugates, either free or 
immobilized to gold nanoparticles, started with determination of their intracellular uptake. 
It was shown that both forms were effectively taken into the cell, although a lower level was 
observed for immobilized forms. To investigate the photodynamic potential of the 
conjugates, SCC were exposed in vitro to photodynamic treatment and cell mortality of post-
PDT cultures was determined. The phototoxicities of unbound porphyrin-brucine 
conjugates were higher than those of conjugates immobilized on gold nanoparticles. This 
reduction of photodynamic efficacy is likely to be a consequence of nanoparticle aggregation 
that occurs in the aqueous cell growth media.  
In contrast, when the PDT effectiveness was tested in vivo, the greatest reduction in tumor 
growth was observed in mice treated with porphyrin conjugates immobilized on gold 
nanoparticles. All tumors were eliminated and no detectable relapse of the primary tumor was 
observed. When animals were treated with unbound conjugates, they exhibited only a 
transient regression in tumor size that lasted until day 18, and then the primary tumors began 
to gradually re-grow. Importantly, mice treated with gold nanoparticles without porphyrin 
exhibited slight tumor retardation in growth that is most likely attributed to the 
photothermal effect described in other systems. Thus, under the in vivo conditions tested, the 
gold nanoparticle-immobilized conjugates were more effective than free conjugates alone. In 
addition, both spectroscopic and ECD studies demonstrated that conjugated nanoparticles 
exhibited a strong interaction with plasma proteins (mainly serum albumin), which led to their 
self-assembly and generation of supramolecular complexes, and thereby to the enhanced 
permeability and retention effect. It further contributed to potent accumulation of immobilized 
conjugates in tumors leading to increased PDT efficacy. Moreover, the direct lethal effect of 
PDT on tumor cells combines well with the nanoscale size of gold-immobilized porphyrins 
that may limit the local blood supply (vascular impairment). 
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